{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:49:34Z","timestamp":1761562174631,"version":"3.40.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.amjcard.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T03:00:37Z","timestamp":1479870037000},"page":"565-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Statins, Ezetimibe, and Proprotein Convertase Subtilisin\u2013Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-5822","authenticated-orcid":false,"given":"James H.","family":"O'Keefe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"DiNicolantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2016.11.001_bib1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/01.ATV.0000012662.29622.00","article-title":"Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study","volume":"22","author":"Jaffer","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2016.11.001_bib2","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.11.001_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4065\/79.1.101","article-title":"Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer","volume":"79","author":"O'Keefe","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2016.11.001_bib4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.amjcard.2016.11.001_bib5","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.11.001_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosissup.2012.10.001","article-title":"The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease","volume":"14","author":"Thompson","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.amjcard.2016.11.001_bib7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nature00804","article-title":"Subendothelial retention of atherogenic lipoproteins in early atherosclerosis","volume":"417","author":"Skalen","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.amjcard.2016.11.001_bib8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/bmj.324.7353.1570","article-title":"Risk factor thresholds: their existence under scrutiny","volume":"324","author":"Law","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2016.11.001_bib9","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.11.001_bib10","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.11.001_bib12","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib13","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib14","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.11.001_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1\u2014Full Report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.amjcard.2016.11.001_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib18","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjcard.2016.11.001_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.11.001_bib20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.11.001_bib21","series-title":"2016 Scientific Sessions of the American Heart Association","article-title":"Effect of evolocumab on progression of coronary atherosclerosis in statin-treated patients: a placebo-controlled intravascular ultrasound trial (GLAOV trial)","author":"Nissen","year":"2016"},{"key":"10.1016\/j.amjcard.2016.11.001_bib22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib23","doi-asserted-by":"crossref","first-page":"914e1","DOI":"10.1016\/j.amjmed.2015.01.034","article-title":"Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?","volume":"128","author":"DiNicolantonio","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib24","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMp1508120","article-title":"Reducing LDL with PCSK9 inhibitors\u2013the clinical benefit of lipid drugs","volume":"373","author":"Everett","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib25","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.11.001_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pcad.2015.04.004","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy","volume":"58","author":"Joseph","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.amjcard.2016.11.001_bib27","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.amjcard.2016.11.001_bib28","first-page":"774","article-title":"PCSK9 inhibitors and cardiovascular events","volume":"373","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.11.001_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jama.284.3.311","article-title":"Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity","volume":"284","author":"Stamler","year":"2000","journal-title":"JAMA"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916318057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916318057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T08:57:30Z","timestamp":1536224250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914916318057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0002914916318057"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.11.001","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins, Ezetimibe, and Proprotein Convertase Subtilisin\u2013Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}